Healthcare · Drug Manufacturers - Specialty & Generic
Price
$16.33
Market Cap
$19.0B
Employees
32,000
Beta
0.90
Avg Volume
10,713,956
CEO
Scott Andrew Smith
Business Description
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-5.44
Stock Price: $16.33
EPS (Diluted): -3.00
EPS (Diluted): -3.00
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.99
Stock Price: $16.33
Total Equity: $14.71B
Shares: 1,170,700,000
Total Equity: $14.71B
Shares: 1,170,700,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
12.30
Market Cap: $19.02B
Total Debt: $14.52B
Cash: $1.35B
EBITDA: -$395.40M
Total Debt: $14.52B
Cash: $1.35B
EBITDA: -$395.40M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$27.9B
Market Cap: $19.02B
Total Debt: $14.52B
Cash: $1.35B
Total Debt: $14.52B
Cash: $1.35B
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
1.02
Stock Price: $16.33
Revenue: $14.30B
Shares: 1,170,700,000
Revenue: $14.30B
Shares: 1,170,700,000
EV/Sales (Total value vs revenue — works when P/E can't)
API1.95
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
35.1%
Gross Profit: $5.01B
Revenue: $14.30B
Revenue: $14.30B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-18.6%
Operating Income: -$2.66B
Revenue: $14.30B
Revenue: $14.30B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-24.6%
Net Income: -$3.51B
Revenue: $14.30B
Revenue: $14.30B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-2.0%
Net Income: -$3.51B
Total Equity: $14.71B
Total Equity: $14.71B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
0.2%
Operating Income: -$2.66B
Tax Rate: 4.1%
Equity: $14.71B
Total Debt: $14.52B
Cash: $1.35B
Tax Rate: 4.1%
Equity: $14.71B
Total Debt: $14.52B
Cash: $1.35B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.30
Current Assets: $9.22B
Current Liabilities: $7.09B
Current Liabilities: $7.09B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.99
Short-Term Debt: $2.04B
Long-Term Debt: $12.48B
Total Debt: $14.52B
Total Equity: $14.71B
Long-Term Debt: $12.48B
Total Debt: $14.52B
Total Equity: $14.71B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$12.21
Revenue: $14.30B
Shares: 1,170,700,000
Shares: 1,170,700,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$12.57
Total Equity: $14.71B
Shares: 1,170,700,000
Shares: 1,170,700,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$1.65
Operating CF: $2.32B
CapEx: -$378.80M
Shares: 1,170,700,000
CapEx: -$378.80M
Shares: 1,170,700,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
3.9%
Last Dividend: N/A
Stock Price: $16.33
Stock Price: $16.33
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$3.51B
Net Income: -$3.51B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VTRS against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| Cost of Revenue | $12.3B | $9.8B | $9.0B | $9.1B | $9.3B |
| Gross Profit | $5.6B | $6.5B | $6.4B | $5.6B | $5.0B |
| Operating Expenses | $5.6B | $4.9B | $5.7B | $5.6B | $7.7B |
| Operating Income | -$34.0M | $1.6B | $766.2M | $10.1M | -$2.7B |
| Net Income | -$1.3B | $2.1B | $54.7M | -$634.2M | -$3.5B |
| EBITDA | $4.5B | $6.4B | $3.5B | $2.8B | -$395.4M |
| EPS | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $701.2M | $1.3B | $991.9M | $734.8M | $1.3B |
| Total Current Assets | $10.9B | $10.6B | $13.0B | $9.5B | $9.2B |
| Total Assets | $54.8B | $50.0B | $47.7B | $41.5B | $37.2B |
| Current Liabilities | $9.9B | $6.7B | $7.8B | $5.8B | $7.1B |
| Long-Term Debt | $19.7B | $18.0B | $16.2B | $14.0B | $12.5B |
| Total Liabilities | $34.4B | $28.9B | $27.2B | $22.9B | $22.5B |
| Total Equity | $20.5B | $21.1B | $20.5B | $18.6B | $14.7B |
| Retained Earnings | $3.7B | $5.2B | $4.6B | $3.4B | -$388.3M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $3.0B | $3.0B | $2.8B | $2.3B | $2.3B |
| Capital Expenditure | -$509.4M | -$489.4M | -$474.5M | -$326.0M | -$378.8M |
| Free Cash Flow | $2.5B | $2.5B | $2.3B | $2.0B | $1.9B |
| Acquisitions (net) | $277.0M | $0 | -$667.7M | -$350.0M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$17.4M | $0 | -$250.0M | -$250.0M | -$500.5M |
| Net Change in Cash | -$143.8M | $556.3M | -$268.9M | -$257.5M | $611.9M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 5:02am (4h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$14.8B $14.7B – $14.8B
|
$15.1B $14.9B – $15.3B
|
$15.4B $15.4B – $15.4B
|
$15.0B $14.9B – $15.1B
|
| EBITDA |
$3.1B $3.1B – $3.1B
|
$3.1B $3.1B – $3.2B
|
$3.2B $3.2B – $3.2B
|
$3.1B $3.1B – $3.1B
|
| Net Income |
$2.9B $2.8B – $3.0B
|
$3.1B $3.0B – $3.2B
|
$3.5B $1.4B – $5.6B
|
$0 |
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -9.1% | -5.1% | -4.5% | -3.0% |
| Gross Profit Growth | +16.5% | -0.9% | -12.7% | -10.8% |
| Operating Income Growth | +4,849.7% | -52.6% | -98.7% | -26,467.3% |
| Net Income Growth | +263.8% | -97.4% | -1,259.4% | -454.2% |
| EBITDA Growth | +43.7% | -45.3% | -19.8% | -114.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 5:02am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-25 | Campbell Paul | S-Sale | 50,076.00 | $16.17 | $809,784 |
| 2026-04-15 | Le Goff Corinne | M-Exempt | 39,344.00 | $0.00 | $0 |
| 2026-04-15 | Le Goff Corinne | M-Exempt | 3,644.00 | $0.00 | $0 |
| 2026-04-15 | Le Goff Corinne | F-InKind | 1,617.00 | $13.86 | $22,412 |
| 2026-04-15 | Le Goff Corinne | F-InKind | 17,450.00 | $13.86 | $241,857 |
| 2026-04-15 | Le Goff Corinne | M-Exempt | 39,344.00 | $0.00 | $0 |
| 2026-04-15 | Le Goff Corinne | M-Exempt | 3,643.83 | $0.00 | $0 |
| 2026-03-23 | Campbell Paul | S-Sale | 21,350.00 | $13.28 | $283,539 |
| 2026-03-06 | Le Goff Corinne | M-Exempt | 44,165.00 | $0.00 | $0 |
| 2026-03-06 | Le Goff Corinne | A-Award | 88,984.00 | $0.00 | $0 |
| 2026-03-06 | Le Goff Corinne | M-Exempt | 44,165.00 | $0.00 | $0 |
| 2026-03-06 | Le Goff Corinne | M-Exempt | 2,193.00 | $0.00 | $0 |
| 2026-03-06 | Le Goff Corinne | F-InKind | 973.00 | $14.16 | $13,778 |
| 2026-03-06 | Le Goff Corinne | F-InKind | 19,588.00 | $14.16 | $277,366 |
| 2026-03-06 | Le Goff Corinne | M-Exempt | 2,192.01 | $0.00 | $0 |
| 2026-03-06 | Mistras Theodora | M-Exempt | 41,711.00 | $0.00 | $0 |
| 2026-03-06 | Mistras Theodora | A-Award | 86,017.00 | $0.00 | $0 |
| 2026-03-06 | Mistras Theodora | M-Exempt | 41,711.00 | $0.00 | $0 |
| 2026-03-06 | Mistras Theodora | M-Exempt | 2,071.00 | $0.00 | $0 |
| 2026-03-06 | Mistras Theodora | F-InKind | 1,146.00 | $14.16 | $16,227 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-22 | $0.12 | 2026-05-04 | 2026-05-22 | 2026-06-17 |
| 2026-03-09 | $0.12 | 2026-02-23 | 2026-03-09 | 2026-03-18 |
| 2025-11-24 | $0.12 | 2025-11-03 | 2025-11-24 | 2025-12-15 |
| 2025-08-22 | $0.12 | 2025-08-04 | 2025-08-22 | 2025-09-15 |
| 2025-05-23 | $0.12 | 2025-05-05 | 2025-05-23 | 2025-06-16 |
| 2025-03-10 | $0.12 | 2025-02-27 | 2025-03-10 | 2025-03-18 |
| 2024-11-22 | $0.12 | 2024-11-04 | 2024-11-22 | 2024-12-13 |
| 2024-08-23 | $0.12 | 2024-08-05 | 2024-08-23 | 2024-09-13 |
| 2024-05-23 | $0.12 | 2024-05-06 | 2024-05-24 | 2024-06-14 |
| 2024-03-08 | $0.12 | 2024-02-26 | 2024-03-11 | 2024-03-18 |
| 2023-11-22 | $0.12 | 2023-11-07 | 2023-11-24 | 2023-12-15 |
| 2023-08-23 | $0.12 | 2023-08-04 | 2023-08-24 | 2023-09-15 |
| 2023-05-23 | $0.12 | 2023-05-05 | 2023-05-24 | 2023-06-16 |
| 2023-03-08 | $0.12 | 2023-02-24 | 2023-03-09 | 2023-03-17 |
| 2022-11-22 | $0.12 | 2022-11-07 | 2022-11-23 | 2022-12-16 |
| 2022-08-23 | $0.12 | 2022-08-04 | 2022-08-24 | 2022-09-16 |
| 2022-05-23 | $0.12 | 2022-05-05 | 2022-05-24 | 2022-06-16 |
| 2022-02-23 | $0.12 | 2022-01-06 | 2022-02-24 | 2022-03-16 |
| 2021-11-22 | $0.11 | 2021-11-08 | 2021-11-23 | 2021-12-16 |
| 2021-08-23 | $0.11 | 2021-08-09 | 2021-08-24 | 2021-09-16 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VTRS — it's generated by the pipeline (
market-narrative step).
No community reviews yet for VTRS.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30